NANO Nanobiotix S.A.

EPA · FR · Healthcare · Biotechnology · nanobiotix.com

23.12EUR+1.14%Mkt Cap: 1.27B $P/E: —Today

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap1.27B USD

Enterprise Value1.26B USD

Revenue (TTM)12.51M USD

Gross Profit12.51M USD

Net Income (TTM)-26.04M USD

Revenue/Share0.24 EUR

Last Price23.12 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees100

CountryFR

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-91.44

PEG—

EV/EBITDA-38.85

EV/Revenue100.56

P/S101.17

P/B-34.79

EPS (TTM)-1.09

EPS (Forward)-0.25

52W Range

13.1029% of range47.66

52W High47.66 EUR

52W Low13.10 EUR

Profitability

Gross Margin100.00%

Oper. Margin-322.88%

EBITDA Margin-258.87%

Profit Margin-80.83%

ROE28.36%

ROA-35.36%

Growth

Revenue Growth-79.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF-36.33M USD

CapEx (TTM)593.48K USD

FCF Margin-284.91%

FCF Yield-2.82%

Net Debt-4.65M USD

Net Debt/EBITDA0.14

Balance Sheet

Debt/Equity-1.13

Current Ratio1.44

Quick Ratio1.40

Book Value/Sh-0.66 EUR

Cash/Share2.18 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)52.20 EUR

Upside (mean)+125.8%

Target Range40.00 EUR – 60.00 EUR

40.00+125.8% to mean60.00

# Analysts5

Ownership

Shares Out.50.92M

Float35.15M

Insiders15.55%

Institutions29.33%

Technical

SMA 5032.55 (-29.0%)

SMA 20028.84 (-19.8%)

Beta0.57

S&P 52W Chg14.58%

Avg Vol (30d)161.35K

Avg Vol (10d)180.69K

Technical Indicators

RSI (14)23.6

MACD-2.0963

MACD Signal-1.5520

MACD Hist.-0.5443

BB Upper34.30 EUR

BB Middle29.48 EUR

BB Lower24.66 EUR

BB Width32.70%

ATR (14)1.956 EUR

Vol Ratio (20d)4.09x